Blinklab Ltd Completes Data Collection for 375 Child ADHD Study

BlinkLab completes recruitment and data collection in European ADHD study

BlinkLab Limited (ASX:BB1) has completed participant recruitment and neurometric data collection for its European ADHD study, conducted in collaboration with Mental Care Group (MCG). Approximately 375 children were enrolled and tested across the study.

The Company confirmed that final study analysis is expected early in Q3 CY 2026, in the coming weeks, following completion of the comprehensive clinical diagnostic review process required to establish the study’s diagnostic reference standard.

Importantly, this update marks the completion of data collection, not the reporting of study outcomes. Results have not yet been disclosed.

Key data points from the update include:

• Approximately 375 children enrolled and tested

• Collaboration partner: Mental Care Group (MCG)

• Final analysis expected: early Q3 CY 2026

• Quality-control review confirmed the dataset is highly consistent, complete and suitable for all planned analyses, with no issues identified

Why this milestone matters for BlinkLab investors

Completing clean, complete neurometric data collection helps de-risk the study and keeps it on track toward a near-term results catalyst. The dataset has passed quality review without flagging any concerns, a positive signal of execution quality.

It is worth noting that this confirms data quality and completeness, not study success. The outcome of the analyses remains pending.

For investors, the key takeaway is the timeline: with data collection finalised, attention now shifts to the results update expected in the coming weeks.

How BlinkLab’s technology fits into ADHD diagnosis

BlinkLab is developing a smartphone-based platform that captures objective, reflex-based neurometric measures in minutes, using artificial intelligence and machine learning. The aim is to provide fast, objective data in a field that has traditionally relied on lengthier specialist-led evaluation.

Current clinical ADHD assessment for children depends on comprehensive specialist evaluations and clinical judgment, which can be subjective and time-consuming. The European study is designed to evaluate BlinkLab’s objective neurometric measures against comprehensive clinical ADHD diagnoses, which form the study’s diagnostic reference standard.

The final stage requires completion of the clinical diagnostic reference dataset. Establishing a comprehensive and accurate reference standard is described by the Company as a necessary component to support robust evaluation of the technology.

The Company references published research on the overdiagnosis of ADHD in children and adolescents, the broader problem of subjective diagnosis that the platform aims to help address.

BlinkLab secured peer-reviewed validation in a Q1-ranked research journal for its smartphone neurometric technology in a 536-child multi-centre study, a scientific credibility milestone that strengthens the evidentiary foundation the European ADHD study is now building upon.

It is worth distinguishing the ADHD work from BlinkLab’s most advanced product, BlinkLab Dx1, which is an autism diagnostic aid. The ADHD study represents an expansion of the platform into a new condition.

The study progression can be summarised as follows:

1. A pilot ADHD study with MCG, referenced from the Company’s 30 July 2024 announcement, identified objective neurometric response patterns in children with ADHD that were distinct from those previously observed in autism studies.

2. These encouraging pilot findings provided the basis for expanding the research into the current, larger clinical study.

3. The current study evaluates BlinkLab’s objective measures against comprehensive clinical ADHD diagnoses.

Chairman points to the problem BlinkLab aims to solve

BlinkLab Non-Executive Chairman Brian Leedman highlighted the contrast between the speed of the Company’s data capture and the longer clinical assessment process.

Brian Leedman, Non-Executive Chairman, BlinkLab

“We’re pleased to have completed recruitment and data collection for this important study. BlinkLab collects objective neurometric data in just minutes, but today’s clinical ADHD assessment process for children and adolescents takes much longer because it relies on comprehensive specialist evaluations and clinical judgment. Study analysis cannot be completed until all clinical diagnoses have been finalized and documented. This is almost complete and highlights the problem BlinkLab is committed to solve: bringing objective, fast measurements to a field that has long relied on subjective, time-consuming assessments. We look forward to reporting the study results in the coming weeks.”

What comes next

The near-term roadmap centres on completing the clinical diagnostic reference dataset, after which the study analyses can proceed toward a results update. The Company expects final analysis early in Q3 CY 2026, in the coming weeks.

BlinkLab has confirmed it will provide a further update once the final diagnostic dataset has been received and the study analyses have been completed.

With data collection finalised and quality confirmed, the pending results represent a near-term catalyst for investors to monitor, though the outcome of the analyses remains to be reported.

The pivotal FDA autism study, which enrolled its first participant in March 2026 across ten leading US clinical centres, is running concurrently with the European ADHD programme, meaning BlinkLab is advancing two major clinical workstreams toward separate results catalysts in 2026 and 2027.

Don’t Miss the Next Healthcare Breakthrough on ASX

Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market and click the “Free Alerts” button at StockWire X to receive the next market-moving update the moment it drops.